Total Payments
$22,410
2023 Payments
$20,596
Companies
16
Transactions
75
Medicare Patients
3,102
Medicare Billing
$384,287
Payment Breakdown by Category
Research$20,596 (91.9%)
Food & Beverage$1,438 (6.4%)
Travel$300.71 (1.3%)
Education$75.30 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,596 | 5 | 91.9% |
| Food and Beverage | $1,438 | 67 | 6.4% |
| Travel and Lodging | $300.71 | 1 | 1.3% |
| Education | $75.30 | 2 | 0.3% |
Payments by Type
Research
$20,596
5 transactions
General
$1,814
70 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $20,633 | 7 | $0 (2023) |
| ABBVIE INC. | $395.52 | 17 | $0 (2022) |
| Apollo Endosurgery US Inc | $377.71 | 3 | $0 (2017) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $295.59 | 22 | $0 (2020) |
| Gilead Sciences, Inc. | $155.77 | 7 | $0 (2019) |
| Allergan Inc. | $153.26 | 2 | $0 (2018) |
| Shire North American Group Inc | $75.30 | 2 | $0 (2017) |
| Nestle HealthCare Nutrition Inc. | $73.42 | 3 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $63.57 | 3 | $0 (2017) |
| Concordia Pharmaceuticals Inc. | $51.37 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20,596 | 5 | PFIZER INC. ($20,596) |
| 2022 | $42.60 | 2 | ABBVIE INC. ($42.60) |
| 2021 | $104.08 | 6 | AbbVie Inc. ($79.11) |
| 2020 | $136.32 | 7 | Nestle HealthCare Nutrition Inc. ($48.45) |
| 2019 | $156.36 | 9 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($72.32) |
| 2018 | $536.68 | 29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($206.70) |
| 2017 | $838.13 | 17 | Apollo Endosurgery US Inc ($377.71) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $5,055.01 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/05/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $7,750.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,660.85 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 08/03/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,706.36 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,423.72 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/19/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: IMMUNOLOGY | ||||||
| 01/07/2022 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $29.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/22/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/28/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/26/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: IMMUNOLOGY | ||||||
| 04/14/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/08/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 01/13/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2020 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/07/2020 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/11/2020 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/30/2020 | RedHill Biopharma Inc. | Movantik (Drug), Talicia | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Opioid Antagonist | ||||||
| 02/05/2020 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 01/29/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/22/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/12/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/20/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/13/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/22/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.00 | General |
| 05/31/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.09 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $12,846 | 4 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $7,750 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 638 | 1,030 | $413,186 | $93,496 |
| 2022 | 11 | 691 | 824 | $365,253 | $79,182 |
| 2021 | 12 | 788 | 970 | $391,166 | $91,741 |
| 2020 | 13 | 985 | 1,282 | $478,499 | $119,867 |
Total Patients
3,102
Total Services
4,106
Medicare Billing
$384,287
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 235 | $49,585 | $22,059 | 44.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 182 | 244 | $111,996 | $14,334 | 12.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 59 | 81 | $32,238 | $11,115 | 34.5% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 56 | 64 | $42,304 | $10,246 | 24.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 141 | $20,586 | $8,827 | 42.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 60 | 67 | $44,220 | $7,505 | 17.0% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 35 | 41 | $27,019 | $5,848 | 21.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 34 | 41 | $11,439 | $4,158 | 36.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 19 | 19 | $15,846 | $3,840 | 24.2% |
| 43247 | Removal of foreign bodies of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 15 | $8,790 | $1,960 | 22.3% |
| 43450 | Dilation of esophagus | Facility | 2023 | 40 | 53 | $14,257 | $1,677 | 11.8% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 12 | 13 | $2,808 | $1,037 | 36.9% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 13 | 16 | $32,098 | $890.91 | 2.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 91 | 103 | $40,994 | $16,235 | 39.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 200 | 250 | $114,750 | $13,245 | 11.5% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2022 | 71 | 80 | $52,880 | $12,961 | 24.5% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 61 | 70 | $46,130 | $9,909 | 21.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 60 | 71 | $19,809 | $7,671 | 38.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 54 | 75 | $15,825 | $6,085 | 38.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 47 | 48 | $31,680 | $5,118 | 16.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 16 | 17 | $14,178 | $3,247 | 22.9% |
| 43450 | Dilation of esophagus | Facility | 2022 | 55 | 67 | $18,023 | $2,108 | 11.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 30 | $4,380 | $1,703 | 38.9% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 13 | 13 | $6,604 | $902.33 | 13.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 94 | 111 | $44,178 | $17,860 | 40.4% |
About Dr. John Delgado, M.D
Dr. John Delgado, M.D is a Gastroenterology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366460958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Delgado, M.D has received a total of $22,410 in payments from pharmaceutical and medical device companies, with $20,596 received in 2023. These payments were reported across 75 transactions from 16 companies. The most common payment nature is "" ($20,596).
As a Medicare-enrolled provider, Delgado has provided services to 3,102 Medicare beneficiaries, totaling 4,106 services with total Medicare billing of $384,287. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Tampa, FL
- Active Since 07/18/2006
- Last Updated 05/12/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1366460958
Products in Payments
- NURTEC ODT (Drug) $20,596
- OVERSTITCH (Device) $377.71
- LINZESS (Drug) $250.84
- XIFAXAN (Drug) $182.00
- Mavyret (Drug) $164.55
- APRISO (Drug) $108.27
- GATTEX (Drug) $75.30
- ZENPEP (Drug) $73.42
- Donnatal (Drug) $51.37
- DEFENDO STERILE SINGLE USE VALVES (Device) $48.04
- Viekira (Drug) $46.13
- INFLECTRA (Biological) $36.79
- Creon (Drug) $29.91
- RELISTOR (Drug) $25.19
- UCERIS FOAM (Drug) $22.58
- XIFAXANIBSD (Drug) $21.12
- ENTYVIO (Biological) $20.95
- Movantik (Drug) $16.83
- VIBERZI (Drug) $16.33
- OCALIVA (Drug) $16.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Tampa
John Jacobs, M.d, M.D
Gastroenterology — Payments: $73,013
Gastroenterology $73,013
Dr. Renee Marchioni Beery, D.o, D.O
Gastroenterology — Payments: $66,910
Gastroenterology $66,910
Dr. Shaffer Mok, M.d, M.D
Gastroenterology — Payments: $35,137
Gastroenterology $35,137
Pushpak Taunk
Gastroenterology — Payments: $25,965
Gastroenterology $25,965
Dr. Roland Shepard, Md, MD
Gastroenterology — Payments: $20,204
Gastroenterology $20,204
Ricardo Prieto, M.d, M.D
Gastroenterology — Payments: $18,202
Gastroenterology $18,202